https://allsci.com/news/biotech/aumolertinib-eu-application-hansoh-resubmits/ AllScien 2026-10-12T17:31:25.776453Z Hansoh resubmits aumolertinib EU marketing application after data protection revocation https://allsci.com/news/clinical-trials/icotrokinra-psoriasis-sustains-pasi-90-response-1/ AllScien 2026-10-12T16:18:54.192529Z J&J's oral Icotyde sustains psoriasis clearance through two years in Phase III trial https://allsci.com/news/licensing-and-partnerships/dituo-biopharmaceutical-strikes-multi-target/ AllScien 2026-10-12T16:10:05.918001Z Roche partners with China's Defand Therapeutics on molecular glue degraders https://allsci.com/news/clinical-trials/nicotinamide-riboside-nopark-trial-finds-worsens/ AllScien 2026-10-12T16:05:41.898630Z NOPARK trial finds nicotinamide riboside worsens outcomes versus placebo in early Parkinson disease https://allsci.com/news/approvals/hovilpri-fda-approval-approves-for/ AllScien 2026-10-12T15:47:17.438886Z FDA approves Asahi Kasei's Hovilpri for treatment-refractory HSV infections https://allsci.com/news/clinical-trials/prifemilast-vs-apremilast-beats-on-both/ AllScien 2026-10-12T15:37:47.574713Z cAMPfield's China partner reports Phase III prifemilast superiority over apremilast in psoriasis https://allsci.com/news/approvals/weltruza-olanzapine-fda-approves-tevas-as-first/ AllScien 2026-10-12T15:11:16.819688Z FDA approves Teva's Weltruza as first once-monthly subcutaneous LAI for schizophrenia https://allsci.com/news/ipo-public-listing/city-therapeutics-ipo-seeks-usd-175m-in-to/ AllScien 2026-10-12T14:39:59.888674Z City Therapeutics seeks USD 175m in IPO to advance RNAi pipeline into 2028 https://allsci.com/news/biotech/chai-discovery-gsk-secures-collaboration-after/ AllScien 2026-10-12T14:34:33.571051Z Chai Discovery lands GSK deal after successful AI binder tests